SCHEMBL20482201

SCHEMBL20482201

Cc1nc2cc(C(C)Cl)ccc2o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.50
GAA P10253 2/20 0.50
RAB9A P51151 7/20 0.44
NPC1 O15118 5/20 0.44
KDM4E B2RXH2 5/20 0.44
MAPT P10636 4/20 0.44
ALDH1A1 P00352 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
TP53 P04637 3/20 0.44
HSD17B10 Q99714 2/20 0.44
OGA O60502 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
STAT1 P42224 1/20 0.42
MAOA P21397 1/20 0.41
ADRA1A P35348 1/20 0.41
TAS1R3 Q7RTX0 3/20 0.40
TAS1R1 Q7RTX1 3/20 0.40
POLB P06746 1/20 0.40
BMPR1B O00238 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30644669 1.00 L3MBTL1 (0.50) L3MBTL1GAARAB9ANPC1KDM4E
SCHEMBL10315087 0.86 MAPT (0.58) L3MBTL1GAARAB9ANPC1KDM4E
SCHEMBL19068834 0.83 L3MBTL1 (0.50) L3MBTL1GAARAB9ANPC1KDM4E
SCHEMBL20481996 0.83 GAA (0.50) L3MBTL1GAARAB9ANPC1KDM4E
SCHEMBL18024194 0.80 GAA (0.47) L3MBTL1GAARAB9ANPC1KDM4E
SCHEMBL10315088 0.80 GAA (0.47) L3MBTL1GAARAB9ANPC1KDM4E
SCHEMBL11624588 0.79 L3MBTL1 (0.46) L3MBTL1GAARAB9ANPC1KDM4E
SCHEMBL24818527 0.78 L3MBTL1 (0.49) L3MBTL1GAARAB9ANPC1KDM4E
SCHEMBL353166 0.74 LMNA (0.61) L3MBTL1GAARAB9ANPC1KDM4E
SCHEMBL31507497 0.74 LMNA (0.61) L3MBTL1GAARAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115604-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2025-04-10 US disclosed
US-12157734-B2 Sulfoximine glycosidase inhibitors ASCENEURON SA (CH) 2024-12-03 US disclosed
US-20220177470-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2022-06-09 US disclosed
US-20220177470-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2022-06-09 US disclosed
US-11261183-B2 Sulfoximine glycosidase inhibitors ASCENEURON SA (CH) 2022-03-01 US disclosed
CN-110770226-A Sulfoximine glycosidase inhibitors 阿森纽荣股份公司 2020-02-07 CN disclosed
WO-2018153508-A2 SULFOXIMINE GLYCOSIDASE INHIBITORS Asceneuron S.A. (CH) 2018-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12157734-B2 Sulfoximine glycosidase inhibitors ENGASE, BACE1, GAA L3MBTL1 2996/4885GAA 3/4885RAB9A 1707/4885
US-20220177470-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ENGASE, BACE1, GAA L3MBTL1 2996/4885GAA 3/4885RAB9A 1707/4885
US-20250115604-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ENGASE, BACE1, GAA L3MBTL1 2460/4885GAA 3/4885RAB9A 1641/4885
US-11261183-B2 Sulfoximine glycosidase inhibitors ENGASE, BACE1, GAA L3MBTL1 2996/4885GAA 3/4885RAB9A 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.